Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients
Contributeurs/tricesDaali, Youssef; Ancrenaz, Virginie; Bosilkovska Weisskopf, Marija; Dayer, Pierre; Desmeules, Jules Alexandre
Publié dansMetabolism, clinical and experimental, vol. 60, no. 11, p. 1584-1589
Date de publication2011
Résumé
Mots-clés
- Bupropion/metabolism/pharmacology
- Dose-Response Relationship, Drug
- Down-Regulation/drug effects
- Drug Interactions
- HIV Infections/drug therapy/metabolism
- HIV Protease Inhibitors/pharmacology/therapeutic use
- Humans
- Metabolic Detoxication, Drug
- Metabolic Networks and Pathways/drug effects
- Microsomes, Liver/drug effects/metabolism/pathology
- Models, Biological
- Piperazines/metabolism/pharmacology
- Purinergic P2Y Receptor Antagonists/pharmacology/therapeutic use
- Ritonavir/pharmacology/therapeutic use
- Thiophenes/metabolism/pharmacology
Citation (format ISO)
DAALI, Youssef et al. Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. In: Metabolism, clinical and experimental, 2011, vol. 60, n° 11, p. 1584–1589. doi: 10.1016/j.metabol.2011.03.015
Identifiants
- PID : unige:20271
- DOI : 10.1016/j.metabol.2011.03.015
- PMID : 21550074
ISSN du journal0026-0495